PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2018

Pretreatment with low-dose fimasartan ameliorates NLRP3 inflammasome-mediated neuroinflammation and brain injury after intracerebral hemorrhage.

Rat / Other

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 30171865 ↗2018Reported benefit

Pretreatment with low-dose fimasartan ameliorates NLRP3 inflammasome-mediated neuroinflammation and brain injury after intracerebral hemorrhage.

RatOtherSprague-DawleyMalen = 113 rats in total across five groups; n = 10 per group for…Oral (p.o.); dissolved in phosphate-buffered saline at 1 mg/mL and diluted with sterile waterLow dose 0.5 mg/kg; regular doses 1.0 and 3.0 mg/kg. In vit…Pretreatment for 30 days before induction of intracerebral haemorrhage

Model: Collagenase IV induced intracerebral haemorrhage, 0.6 U in 1 microlitre saline injected intrastriatally (3.0 mm left, 0.2 mm posterior to bregma, 6.0 mm depth)

Low-dose fimasartan (0.5 mg/kg) did not change mean blood pressure (97 mmHg versus 97 mmHg in control) yet reduced brain water content at 3 days (81.6 versus 82.0 per cent), improved mNSS at all time points and improved forelimb placing at day 3 (33.8 versus 25.6). It suppressed NF-kB and COX-2 act…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.